ROCKVILLE, Md., Jan. 12, 2021 /PRNewswire/ -- REGENXBIO Inc.
(Nasdaq: RGNX) today announced the closing of its previously
announced underwritten public offering of 4,260,000 shares of its
common stock at a price to the public of $47.00 per share, as well as the exercise in full
of the underwriters' option to purchase 639,000 additional shares
at the public offering price. Including the option exercise, the
total gross proceeds to REGENXBIO are expected to be approximately
$230.3 million, before deducting the
underwriting discounts and commissions and estimated offering
expenses.
BofA Securities, Morgan Stanley and Barclays acted as joint
book-running managers of the offering. Raymond James acted as lead manager of the
offering.
The securities described above were offered by REGENXBIO
pursuant to a shelf registration statement on Form S-3 that was
filed with the Securities and Exchange Commission (the "SEC") on
August 8, 2018 (File No. 333-226691)
and became automatically effective upon filing. A final prospectus
supplement relating to and describing the terms of the offering was
filed with the SEC and is available on the SEC's website at
www.sec.gov. Copies of the final prospectus supplement and the
accompanying prospectus relating to this offering may be obtained
from: BofA Securities at NC1-004-03-43, 200 North College Street,
3rd floor, Charlotte, NC
28255-0001, Attention: Prospectus Department or by email at
dg.prospectus_requests@baml.com; Morgan Stanley at Attention:
Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY, 10014; or Barclays Capital Inc.,
c/o Broadridge Financial Solutions, at 1155 Long Island Avenue,
Edgewood, New York 11717 or by
email at barclaysprospectus@broadridge.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy any of these securities, nor shall
there be any sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the applicable securities
laws of such state or jurisdiction.
About REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology
Platform in the development of a broad pipeline of candidates in
multiple therapeutic areas.
Forward-Looking Statements
This press release includes
"forward-looking statements," within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These statements
express a belief, expectation or intention and are generally
accompanied by words that convey projected future events or
outcomes such as "believe," "may," "will," "estimate," "continue,"
"anticipate," "assume," "design," "intend," "expect," "could,"
"plan," "potential," "predict," "seek," "should," "would" or by
variations of such words or by similar expressions. The
forward-looking statements include statements relating to, among
other things, REGENXBIO's offering of its common stock. REGENXBIO
has based these forward-looking statements on its current
expectations and assumptions as well as other factors REGENXBIO
believes are appropriate under the circumstances. However, whether
actual results and developments will conform with REGENXBIO's
expectations and predictions is subject to a number of risks and
uncertainties, many of which are beyond the control of REGENXBIO.
For a discussion of these risks, refer to the "Risk Factors" and
"Management's Discussion and Analysis of Financial Condition and
Results of Operations" sections of REGENXBIO's Annual Report on
Form 10-K for the year ended December 31,
2019 and Quarterly Report on Form 10-Q for the quarter ended
September 30, 2020 and other filings
with the SEC, which are available on the SEC's website at
www.sec.gov. All of the forward-looking statements made in this
press release are expressly qualified by the cautionary statements
contained or referred to herein. The actual results or developments
anticipated may not be realized or, even if substantially realized,
may not have the expected consequences to or effects on REGENXBIO
or its businesses or operations. Such statements are not guarantees
of future performance and actual results or developments may differ
materially from those projected in the forward-looking statements.
Readers are cautioned not to rely too heavily on the
forward-looking statements contained in this press release. These
forward-looking statements speak only as of the date of this press
release. Except as required by law, REGENXBIO does not undertake
any obligation, and specifically declines any obligation, to update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
Contacts:
Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com
Investors:
Eleanor Barisser, 212-600-1902
eleanor@argotpartners.com
Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/regenxbio-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-301206847.html
SOURCE REGENXBIO Inc.